Considering the evolving field of drug development and genomic data, the European Society for Medical Oncology (ESMO) Precision Medicine Working Group (PMWG) sought to update recommendations for the use  f next-generation
sequencing (NGS) for patients with metastatic cancers published in 2020. After several discussions among the members of the group, a consensus was reached to adopt the same methodology as per the previous publication.1